DUBLIN, Feb. 15, 2018 /PRNewswire/ --
The "Biosimilar Insulin Market Access" report has been added to ResearchAndMarkets.com's offering.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba.
More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations. As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers' formularies and contracts.
Key Topics Covered:
EXECUTIVE SUMMARY
US
- Insights and strategic recommendations
- US payers are adopting a wait-and-see approach for biosimilar Basaglar
- Bibliography
FIVE MAJOR EU MARKETS
- Insights and strategic recommendations
- Uptake of biosimilar insulin varies across EU markets as the EMA does not determine interchangeability
- Physicians and payers have varying views on the interchangeability of biosimilar insulins, but see large opportunities to
- reduce costs
- Payers use biosimilars to pressure originators on pricing
- Pharmacies continue to procure both biosimilars and originators; dynamic pricing environment observed
- Patient switching requires significant discounts of at least 30%
- Given attractive discounts, payers will use a variety of market access tools to drive Basaglar's uptake
- Bibliography
METHODOLOGY
For more information about this report visit https://www.researchandmarkets.com/research/3n6bh8/biosimilar?w=5
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
